Abstract
The severe acute respiratory syndrome coronavirus 2 virus spread fast around the globe. The medical community is actively searching for an antiviral that could be effective against it. An antiviral drug called favipiravir, created for the treatment of influenza, may work well for coronavirus disease 2019 (COVID-19). Therefore, this study evaluated the safety and efficacy of favipiravir in COVID-19 by reviewing published articles. We found favipiravir is effective, safe, and tolerated against COVID-19. More information is needed to determine long-term consequences, such as QT prolongation, hyperuricemia, and teratogenicity. Favipiravir interacts with other medications such as repaglinide, pyrazinamide, theophylline, acyclovir, warfarin, and methotrexate. Physicians should be aware when prescribing it.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Medicine in Developing Countries
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
